\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesPrincipal Investigators with a main European Research Council grant that is ongoing or ended less than 12 months before 1 January of the call year are eligible to participate in an ERC Proof of Concept Grant. The ERC Proof of Concept Grants aim at facilitating exploration of the commercial and social innovation potential of ERC funded research and are therefore available only to PIs whose proposals draw substantially on their ERC funded research. The results of the 2023 Proof of Concept call (3rd cut-off deadline 21 September 2023) were published. In total 102 ERC Proof of Concept Grants were announced of which four received by researchers based at a Flemish host institution. In the ERCEA news articles more background on the evaluation results, the results of all three rounds of the 2023 call and several project examples are highlighted.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health EIT AI Continent Deployment: Best use of technologies
EIT Health’s Innovation Uptake Call focuses on mature digital, data-driven and AI-powered solutions and seeks to support the last steps towards commercialisation. Applicants must apply as a consortium of at least two independent legal entities from different countries. The consortium must include partners from at least two sides of the Knowl... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
